Secondary prevention medication after myocardial infarction: Persistence in elderly people over the course of 1 year

Drugs and Aging

Volumn 31, Issue 7, 2014, Pages 513-525

  Al Khadra, Saba ^a,b   Meisinger, Christa ^a,b   Amann, Ute ^a,b   Holle, Rolf ^b   Kuch, Bernhard ^a,c   Seidl, Hildegard ^b   Kirchberger, Inge ^a,b  

^a KLINIKUM AUGSBURG   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c Hospital of Nördlingen   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIURETIC AGENT;

ACUTE HEART INFARCTION; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; GERIATRIC PATIENT; HEALTH CARE SYSTEM; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; SELF REPORT; SURVIVAL PREDICTION; SURVIVOR; VERY ELDERLY; AMBULATORY CARE; DRUG COMBINATION; MEDICATION COMPLIANCE; MYOCARDIAL INFARCTION;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; GENERAL PRACTITIONERS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEDICATION ADHERENCE; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; SECONDARY PREVENTION;

EID: 84903761874     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-014-0189-x     Document Type: Article

References (45)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18-209. doi:10.1161/CIR.0b013e3182009701.
2. Allender S, Scarborough P, Peto V, Rayner M, Leal J, Luengo-Fernandez R, Gray A. European cardiovascular disease statistics: 2008 edition. Oxford: Department of Public Health, University of Oxford; 2008 [online]. Available from: http://www.herzstiftung.ch/uploads/media/European-cardiovascular-disease- statistics-2008.pdf.
3. Bonaca MP, Wiviott SD, Braunwald E, Murphy SA, Ruff CT, Antman EM, Morrow DA. American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel- thrombolysis in myocardial infarction 38). Circulation. 2012;125(4):577-83. doi:10.1161/CIRCULATIONAHA.111.041160.
4. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318(7200):1730-7. (Pubitemid 29290470)
5. Bramlage P, Messer C, Bitterlich N, Pohlmann C, Cuneo A, Stammwitz E, Tebbenjohanns J, Gohlke H, Senges J, Tebbe U. The effect of optimal medical therapy on 1-year mortality after acute myocardial infarction. Heart. 2010;96(8):604-9. doi:10.1136/hrt.2009.188607.
6. Tuppin P, Neumann A, Danchin N, de Peretti C, Weill A, Ricordeau P, Allemand H. Evidence-based pharmacotherapy after myocardial infarction in France: adherence-associated factors and relationship with 30-month mortality and rehospitalization. Arch Cardiovasc Dis. 2010;103(6-7):363-75 (S1875-2136(10)00114-2).
7. van der Elst ME, Bouvy ML, de Blaey CJ, de Boer A. Effect of drug combinations on admission for recurrent myocardial infarction. Heart. 2007;93(10):1226-30 (epub 13 May 2007).
8. Choudhry NK, Avorn J, Glynn RJ, Antman EM, Schneeweiss S, Toscano M, Reisman L, Fernandes J, Spettell C, Lee JL, Levin R, Brennan T, Shrank WH. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365(22):2088-97. doi:10.1056/NEJMsa1107913.
9. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007;116(7):e148-304. doi:10.1161/CIRCULATIONAHA.107.181940.
10. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J. 2007;28:1598-660. (Pubitemid 47227122)
11. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M. ESC guidelines on management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Rev Esp Cardiol. 2009;62(3):293 (e291-247, pii 13133305).
12. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation. 2008;117(2):296-329. doi:10.1161/CIRCULATIONAHA.107.188209.
13. Vedin O, Hagström E, Stewart R, Brown R, Krug-Gourley S, Davies R, Wallentin L, White H, Held C. Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study. Eur J Prev Cardiol. 2013;20(4):678-85.
14. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009;16(2):121-37. doi:10.1097/HJR. 0b013e3283294b1d.
15. Simpson E, Beck C, Richard H, Eisenberg MJ, Pilote L. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J. 2003;145:438-44. (Pubitemid 36390489)
16. Mangiapane S, Busse R. Prescription prevalence and continuing medication use for secondary prevention after myocardial infarction: the reality of care revealed by claims data analysis. Dtsch Arztebl Int. 2011;108(50):856-62. doi:10.3238/arztebl.2011.0856.
17. Kirchmayer U, Agabiti N, Belleudi V, Davoli M, Fusco D, Stafoggia M, Arca M, Barone AP, Perucci CA. Socio-demographic differences in adherence to evidence-based drug therapy after hospital discharge from acute myocardial infarction: a population-based cohort study in Rome, Italy. J Clin Pharm Ther. 2012;37(1):37-44. doi:10.1111/j.1365-2710.2010.01242.x.
18. Sirois C, Moisan J, Poirier P, Gregoire JP. Underuse of cardioprotective treatment by the elderly with type 2 diabetes. Diabetes Metab. 2008;34(2):169-76. doi:10.1016/S1262-3636(08)00039-6.
19. Kirchberger I, Meisinger C, Seidl H, Wende R, Kuch B, Holle R. Nurse-based case management for aged patients with myocardial infarction: study protocol of a randomized controlled trial. BMC Geriatr. 2010;10:29 (pii 1471-2318-10-29).
20. Meisinger C, Stollenwerk B, Kirchberger I, Seidl H, Wende R, Kuch B, Holle R. Effects of a nurse-based case management compared to usual care among aged patients with myocardial infarction: results from the randomized controlled KORINNA study. BMC Geriatr. 2013;13(1):115.
21. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461-70 (pii 199903160-00002).
22. Kuch B, von Scheidt W, Kling B, Heier M, Hoermann A, Meisinger C. Characteristics and outcome of patients with acute myocardial infarction according to presenting electrocardiogram (from the MONICA/KORA Augsburg Myocardial Infarction - Registry). Am J Cardiol. 2007;100(7):1056-60 (pii S0002-9149(07)01246-5).
23. Sheikh JI, Yesavage JA. A knowledge assessment test for geriatric psychiatry. Hosp Community Psychiatry. 1985;36:1160-6.
24. Cramer J, Roy A, Burrell A, Menown I, Kassianos G, Padmanabhan S, Gupta S, Lang CC. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-7. (Pubitemid 351160875)
25. Gislason GH, Rasmussen JN, Abildstrøm SZ, Gadsbøll N, Buch P, Friberg J, Rasmussen S, Køber L, Stender S, Madsen M, Torp-Pedersen C. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J. 2006;27(10):1153-8 (epub 6 Jan 2006).
26. Kalra PR, Morley C, Barnes S, Menown I, Kassianos G, Padmanabhan S, Gupta S, Lang CC. Discontinuation of beta-blockers in cardiovascular disease: UK primary care cohort study. Int J Cardiol. 2012. doi:10.1016/j.ijcard.2012.06. 116.
27. Anatomisch-therapeutisch-chemische Klassifikation (ATC). Wissenschaftliches Institut der AOK. http://www.wido.de/arz-atcddd-klassifi. html. Accessed 27 May 2013.
28. Allison PD. Logistic regression using the SAS system: theory and application. Cary: SAS Institute; 1999.
29. Bischoff B, Silber S, Richartz BM, Pieper L, Klotsche J, Wittchen HU, DETECT Study-Group. Inadequate medical treatment of patients with coronary artery disease by primary care physicians in Germany. Clin Res Cardiol. 2006;95(8):405-12 (epub 3 Jul 2006).
30. Bauer T, Gitt AK, Junger C, Zahn R, Koeth O, Towae F, Schwarz AK, Bestehorn K, Senges J, Zeymer U. Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: predictors and outcomes of nonadherence. Eur J Cardiovasc Prev Rehabil. 2010;17(5):576-81. doi:10.1097/HJR.0b013e328338e5da.
31. Meisinger C, Heier M, von Scheidt W, Kirchberger I, Hormann A, Kuch B. Gender-specific short and long-term mortality in diabetic versus nondiabetic patients with incident acute myocardial infarction in the reperfusion era (the MONICA/KORA Myocardial Infarction Registry). Am J Cardiol. 2010;106(12):1680-4 (pii S0002-9149(10)01610-3).
32. Kuepper-Nybelen J, Hellmich M, Abbas S, Ihle P, Griebenow R, Schubert I. Association of long-term adherence to evidence-based combination drug therapy after acute myocardial infarction with all-cause mortality. A prospective cohort study based on claims data. Eur J Clin Pharmacol. 2012;68(10):1451-60. doi:10.1007/s00228-012-1274-x.
33. Spencer FA, Lessard D, Yarzebski J, Gore JM, Goldberg RJ. Decade-long changes in the use of combination evidence-based medical therapy at discharge for patients surviving acute myocardial infarction. Am Heart J. 2005;150(4):838-44 (pii S0002-8703(04)00814-2).
34. Gislason GH, Abildstrom SZ, Rasmussen JN, Rasmussen S, Buch P, Gustafsson I, Friberg J, Gadsbøll N, Køber L, Stender S, Madsen M, Torp-Pedersen C. Nationwide trends in the prescription of beta-blockers and angiotensin-converting enzyme inhibitors after myocardial infarction in Denmark, 1995-2002. Scand Cardiovasc J. 2005;39(1-2):42-9. (Pubitemid 40662735)
35. Boggon R, van Staa TP, Timmis A, Hemingway H, Ray KK, Begg A, Emmas C, Fox KA. Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction - a hospital registry-primary care linked cohort (MINAP-GPRD). Eur Heart J. 2011;32(19):2376-86 (pii ehr340).
36. Macchia A, Romero M, D'Ettorre A, Mariani J, Tognoni G. Temporal trends of the gaps in post-myocardial infarction secondary prevention strategies of co-morbid and elderly populations vs. younger counterparts: an analysis of three successive cohorts between 2003 and 2008. Eur Heart J. 2012;33(4):515-22 (pii ehr410).
37. Newby LK, LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER, Muhlbaier LH, Califf RM. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113(2):203-12. doi:10.1161/CIRCULATIONAHA.105.505636 (epub 9 Jan 2006).
38. Soumerai SB, McLaughlin TJ, Spiegelman D, Hertzmark E, Thibault G, Goldman L. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA. 1997;277:115-21. (Pubitemid 27030178)
39. Setoguchi S, Glynn RJ, Avorn J, Mittleman MA, Levin R, Winkelmayer WC. Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. J Am Coll Cardiol. 2008;51(13):1247-54. doi:10.1016/S0735-1097(08)00229-5. (Pubitemid 351400891)
40. Aronow WS. Beta-blockers, angiotensin-converting enzyme inhibitors, and calcium antagonists in treatment of elderly patients with acute myocardial infarction. Coron Artery Dis. 2000;11(4):331-8. (Pubitemid 30410230)
41. Scherrer JF, Chrusciel T, Garfield LD, Freedland KE, Carney RM, Hauptman PJ, Bucholz KK, Owen R, Lustman PJ. Treatment-resistant and insufficiently treated depression and all-cause mortality following myocardial infarction. Br J Psychiatry. 2012;200(2):137-42. doi:10.1192/bjp.bp.111.096479 (epub 12 Jan 2012).
42. Daugherty SL, Ho PM, Spertus JA, Jones PG, Bach RG, Krumholz HM, Peterson ED, Rumsfeld JS, Masoudi FA. Association of early follow-up after acute myocardial infarction with higher rates of medication use. Arch Intern Med. 2008;168(5):485-91 (discussion 492; pii 168/5/485).
43. Clark A. Ageism and age discrimination in primary and community health care in the United Kingdom. A review from the literature. Department of Health, Centre for Policy on Ageing; 2009:1-90, p 17. http://www.cpa.org.uk/information/ reviews/CPA-ageism-and-age-discrimination-in-primary-and-community-health-care- report.pdf. Accessed 27 May 2013.
44. Col N, Fanale JE, Kronholm P. The role of medication non-compliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med. 1990;150(4):841-5. (Pubitemid 20122061)
45. Austin PC, Tu JV, Ko DT, Alter DA. Factors associated with the use of evidence-based therapies after discharge among elderly patients with myocardial infarction. CMAJ. 2008;179(9):901-8 (pii 179/9/901).